Alps Advisors Inc Allovir, Inc. Transaction History

Alps Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$3.94 - $7.05 $11,303 - $20,226	-2,869 Reduced 4.54%	60,286 $237,000
Q4 2022 Feb 14, 2023	BUY	$4.7 - $9.98 $57,908 - $122,963	12,321 Added 24.24%	63,155 $323,000
Q3 2022 Nov 14, 2022	BUY	$4.13 - $8.79 $49,667 - $105,708	12,026 Added 30.99%	50,834 $401,000
Q2 2022 Aug 11, 2022	SELL	$3.26 - $7.06 $92,430 - $200,172	-28,353 Reduced 42.22%	38,808 $151,000
Q1 2022 May 16, 2022	SELL	$6.75 - $13.52 $55,505 - $111,174	-8,223 Reduced 10.91%	67,161 $453,000
Q4 2021 Feb 09, 2022	SELL	$12.94 - $25.99 $57,207 - $114,901	-4,421 Reduced 5.54%	75,384 $975,000
Q3 2021 Nov 15, 2021	SELL	$16.97 - $25.06 $100,971 - $149,107	-5,950 Reduced 6.94%	79,805 $2 Million
Q2 2021 Aug 11, 2021	SELL	$19.44 - $25.06 $622,702 - $802,721	-32,032 Reduced 27.19%	85,755 $1.69 Million
Q1 2021 May 07, 2021	BUY	$20.81 - $45.5 $2,185 - $4,777	105 Added 0.09%	117,787 $2.76 Million
Q4 2020 Feb 03, 2021	BUY	$23.94 - $46.81 $2.82 Million - $5.51 Million	117,682 New	117,682 $4.52 Million

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.